Safety and efficacy of nabilone for acute chemotherapy‐induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review
Authors:
- 26 July 2018
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (12) , e27374
Abstract
Objectives: To describe the safety and efficacy of nabilone given to pediatric patients to prevent acute chemotherapy‐induced nausea and vomiting (CINV).Methods: A multicenter, retrospective review of pediatric patients who received nabilone for acute CINV prophylaxis between December 1, 2010 and August 1, 2015 was undertaken. One course of nabilone was evaluated per patient. Adverse effects associated with nabilone use were noted. The proportion of patients who experienced complete acute chemotherapy‐induced vomiting (CIV) control during the acute phase was determined. The acute phase was defined as starting with the first chemotherapy dose and continuing until 24 h after administration of the last chemotherapy dose of the chemotherapy block.Results: One hundred ten eligible patients (median age: 14.0 years, range: 1.1–18.0 years; 65 male) were identified. Most (109/110) received nabilone plus a 5‐HT3 antagonist for CINV prophylaxis. Adverse effects associated with nabilone were experienced by 34% (37/110) of children. All were of CTCAE Version 4.03 Grade 2 or less. Sedation (20.0%), dizziness (10.0%), and euphoria (3.6%) were the most commonly reported adverse events. Nabilone was discontinued in 10 patients due to an adverse event. The proportions of patients receiving highly or moderately emetogenic chemotherapy who experienced complete acute CIV control were 50.6% (42/83) and 53.8% (14/26), respectively.Conclusion: Adverse events associated with nabilone were common but of minor clinical significance. Acute CIV control in children receiving nabilone as a part of their antiemetic regimen was poor. Future work should focus on implementation of guideline‐consistent CINV prophylaxis and treatment.Keywords
This publication has 15 references indexed in Scilit:
- Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy‐Induced Nausea and Vomiting in Children With CancerPediatric Blood & Cancer, 2016
- Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children's Oncology GroupPediatric Blood & Cancer, 2016
- Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapyCochrane Database of Systematic Reviews, 2015
- Characterization of Dronabinol Usage in a Pediatric Oncology PopulationThe Journal of Pediatric Pharmacology and Therapeutics, 2015
- Adverse Health Effects of Marijuana UseNew England Journal of Medicine, 2014
- Regulation of nausea and vomiting by cannabinoids and the endocannabinoid systemEuropean Journal of Pharmacology, 2014
- Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patientsPediatric Blood & Cancer, 2013
- Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patientsPediatric Blood & Cancer, 2011
- An efficient new cannabinoid antiemetic in pediatric oncologyLife Sciences, 1995
- Nabilone: an alternative antiemetic for cancer chemotherapy.Archives of Disease in Childhood, 1986